HIV chemokine receptor inhibitors as novel anti-HIV drugs.

The chemokine receptors CXCR4 and CCR5 are the main coreceptors used by the T-cell-tropic (CXCR4-using, X4) and macrophage-tropic (CCR5-using, R5) HIV-1 strains, respectively, for entering their CD4+ target cells. In this review, we focus on the function of these chemokine receptors in HIV infection and their role as novel targets for viral inhibition. Besides some modified chemokines with antiviral activity, several low-molecular weight CCR5 and CXCR4 antagonistic compounds have been described with potent antiviral activity. The best CXCR4 antagonists described are the bicyclam derivatives, which consistently block X4 but also R5/X4 viral replication in PBMCs. We believe that chemokine receptor antagonists will become important new antiviral drugs to combat AIDS. Both CXCR4 and CCR5 chemokine receptor inhibitors will be needed in combination and even in combinations of antiviral drugs that also target other aspects of the HIV replication cycle to obtain optimum antiviral therapeutic effects.

[1]  E. De Clercq,et al.  The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication , 1996, Journal of virology.

[2]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[3]  E. De Clercq,et al.  Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. , 1997, Antiviral research.

[4]  R. Pomerantz,et al.  Twenty years of therapy for HIV-1 infection , 2003, Nature Medicine.

[5]  P. Charneau,et al.  Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons , 1992, Journal of virology.

[6]  Steven M. Wolinsky,et al.  Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures , 1996, Nature Medicine.

[7]  Dominique Schols,et al.  Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[8]  Hassan Mohammad Naif,et al.  HIV gp120 receptors on human dendritic cells. , 2001, Blood.

[9]  S. J. Clark,et al.  Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[10]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[11]  R. Pomerantz,et al.  Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1. , 2003, Virology.

[12]  M. L. Penn,et al.  Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease , 2000, Journal of Virology.

[13]  Douglas D. Richman,et al.  HIV chemotherapy : AIDS , 2001 .

[14]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[15]  E. De Clercq,et al.  Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. , 1996, Antiviral research.

[16]  I. Jones,et al.  Protein-disulfide Isomerase-mediated Reduction of Two Disulfide Bonds of HIV Envelope Glycoprotein 120 Occurs Post-CXCR4 Binding and Is Required for Fusion* , 2003, The Journal of Biological Chemistry.

[17]  D. Littman.  Chemokine Receptors: Keys to AIDS Pathogenesis? , 1998, Cell.

[18]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[19]  Michel Klein,et al.  Changing Virus‐Host Interactions in the Course of HIV‐1 Infection , 1994, Immunological reviews.

[20]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[21]  C. Chitnis,et al.  A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. , 1993, Science.

[22]  R. Nibbs,et al.  Aminooxypentane Addition to the Chemokine Macrophage Inflammatory Protein-1αP Increases Receptor Affinities and HIV Inhibition* , 2000, The Journal of Biological Chemistry.

[23]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Arts,et al.  Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminooxypentane RANTES , 2001, Journal of Virology.

[25]  Q. Sattentau.  HIV gp120: double lock strategy foils host defences. , 1998, Structure.

[26]  X Zhang,et al.  A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. , 1998, Biochemical and biophysical research communications.

[27]  J. Sodroski,et al.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.

[28]  E. De Clercq,et al.  Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 , 1994, Antimicrobial Agents and Chemotherapy.

[29]  S. Nishikawa,et al.  Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.

[30]  E. De Clercq,et al.  Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. , 1999, The Journal of clinical investigation.

[31]  M. Jensen,et al.  Predicting HIV-1 coreceptor usage with sequence analysis. , 2003, AIDS reviews.

[32]  T L Hoffman,et al.  Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.

[34]  E. De Clercq,et al.  A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. , 2000, Molecular pharmacology.

[35]  Masahiko Kuroda,et al.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.

[36]  P. Leder,et al.  The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation , 1995, The Journal of experimental medicine.

[37]  E. De Clercq,et al.  Coreceptor Phenotype of Natural Human Immunodeficiency Virus with Nef Deleted Evolves In Vivo, Leading to Increased Virulence , 2002, Journal of Virology.

[38]  Sharon Engel,et al.  A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo , 2000, Nature Immunology.

[39]  E. De Clercq,et al.  Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. , 1995, Journal of medicinal chemistry.

[40]  G Vassart,et al.  Molecular cloning and functional expression of a new human CC-chemokine receptor gene. , 1996, Biochemistry.

[41]  Y. Soda,et al.  Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection. , 1998, Biochemical and biophysical research communications.

[42]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Doms,et al.  Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1) , 1997, Immunologic research.

[44]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[45]  Edward J. Fuchs,et al.  Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers , 2000, Antimicrobial Agents and Chemotherapy.

[46]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[47]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[48]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[49]  M. L. Penn,et al.  CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[51]  R. Siliciano,et al.  The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.

[52]  M. Greenberg,et al.  Evolution of the Human Immunodeficiency Virus Type 1 Envelope during Infection Reveals Molecular Corollaries of Specificity for Coreceptor Utilization and AIDS Pathogenesis , 2000, Journal of Virology.

[53]  D J Hu,et al.  The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. , 1996, JAMA.

[54]  Hassan Mohammad Naif,et al.  Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages. , 1998, Journal of immunology.

[55]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[56]  E. De Clercq,et al.  In Vivo Evolution of Human Immunodeficiency Virus Type 1 toward Increased Pathogenicity through CXCR4-Mediated Killing of Uninfected CD4 T Cells , 2003, Journal of Virology.

[57]  M. Lederman,et al.  Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5 , 2004, Science.

[58]  S. O’Brien,et al.  Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for CCR5 Δ32 , 1998, Journal of Virology.

[59]  Dominique Schols,et al.  Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist , 2004, Journal of Virology.

[60]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[61]  E. De Clercq,et al.  The LD78β Isoform of MIP-1α Is the Most Potent CC-Chemokine in Inhibiting CCR5-Dependent Human Immunodeficiency Virus Type 1 Replication in Human Macrophages , 2001, Journal of Virology.

[62]  R. Weiss,et al.  Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus , 1991, Virology.

[63]  D. S. Garrett,et al.  High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. , 1994, Science.

[64]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[65]  J. Balzarini,et al.  Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. , 2002, Antiviral research.

[66]  B. Walker,et al.  Enhanced Inhibition of Human Immunodeficiency Virus Type 1 by Met-Stromal-Derived Factor 1β Correlates with Down-Modulation of CXCR4 , 1999, Journal of Virology.

[67]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[68]  M. Montjovent,et al.  Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist (*) , 1996, The Journal of Biological Chemistry.

[69]  Serena Xu,et al.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[71]  H. Heng,et al.  A novel human gene encoding a G-protein-coupled receptor (GPR15) is located on chromosome 3. , 1996, Genomics.

[72]  E. De Clercq,et al.  CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. , 1998, Antiviral research.

[73]  Miriam K. Konkel,et al.  The Orphan Seven-Transmembrane Receptor Apj Supports the Entry of Primary T-Cell-Line-Tropic and Dualtropic Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[74]  A. Iversen,et al.  Dual effect of CCR5 Δ32 gene deletion in HIV-1-infected patients , 1997, The Lancet.

[75]  A. Garzino-Demo,et al.  Beta-chemokines and protection from HIV type 1 disease. , 1998, AIDS research and human retroviruses.

[76]  C. Combadière,et al.  Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP‐1α, MIP‐1β, and RANTES , 1996, Journal of leukocyte biology.

[77]  M. Baba,et al.  T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure , 1999, Journal of Virology.

[78]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[79]  R. Weiss.  Gulliver's travels in HIVland , 2001, Nature.

[80]  A. Rot.  Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. , 1992, Immunology today.

[81]  B. Rovin,et al.  The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .

[82]  E. De Clercq,et al.  Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4 , 1999, Journal of Virology.

[83]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[84]  S. Climie,et al.  Antiherpetic activities of N-alpha-acetyl-nona-D-arginine amide acetate. , 1995, Drugs under experimental and clinical research.

[85]  Knudsen,et al.  Chemokine Receptors and their Crucial Role in Human Immunodeficiency Virus Infection: Major Breakthroughs in HIV Research , 1998, Scandinavian journal of immunology.

[86]  E. De Clercq,et al.  Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[87]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[88]  N. Yoshida,et al.  A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection , 1997, The Journal of experimental medicine.

[89]  R. Doms,et al.  Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins , 2003, Journal of Virology.

[90]  R. Doms,et al.  A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.

[91]  H. Schuitemaker,et al.  Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR , 1995, Journal of clinical microbiology.

[92]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[93]  R. Nibbs,et al.  Characterization of mouse CCX‐CKR, a receptor for the lymphocyte‐attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP‐3β/mCCL19: comparison to human CCX‐CKR , 2002, European journal of immunology.

[94]  M. Baggiolini.  Chemokines and leukocyte traffic , 1998, Nature.

[95]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[96]  E. De Clercq,et al.  Role of CXCR4 in Cell-Cell Fusion and Infection of Monocyte-Derived Macrophages by Primary Human Immunodeficiency Virus Type 1 (HIV-1) Strains: Two Distinct Mechanisms of HIV-1 Dual Tropism , 1999, Journal of Virology.

[97]  E. De Clercq,et al.  The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. , 1999, The Journal of clinical investigation.

[98]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[99]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[100]  R. Doms,et al.  Safe use of the CXCR4 inhibitor ALX40-4C in humans. , 2001, AIDS research and human retroviruses.

[101]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[102]  Klaus Ley,et al.  Chemokines and chemokine receptors in leukocyte trafficking. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[103]  R. Hubbard,et al.  Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. , 1999, Biochemistry.

[104]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[105]  Hiroaki Mitsuya,et al.  Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5* , 2001, The Journal of Biological Chemistry.

[106]  J. Albert,et al.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.

[107]  Robin A. Weiss,et al.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.

[108]  L. Heyndrickx,et al.  Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin , 1990, Journal of virology.

[109]  J. Karn,et al.  An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[110]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[111]  R. Doms,et al.  An Orphan Seven-Transmembrane Domain Receptor Expressed Widely in the Brain Functions as a Coreceptor for Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus , 1998, Journal of Virology.

[112]  E. De Clercq,et al.  Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 , 2002, FEBS letters.

[113]  R. Doms.  Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. , 2000, Virology.

[114]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[115]  I. De Meester,et al.  CD26, let it cut or cut it down. , 1999, Immunology today.

[116]  E. De Clercq,et al.  Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120 , 1997, Antimicrobial agents and chemotherapy.

[117]  E. Clercq.  The bicyclam AMD3100 story , 2003, Nature Reviews Drug Discovery.

[118]  K. Peden,et al.  STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.

[119]  R. Bronson,et al.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[120]  R. Doms,et al.  A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains , 1996, Journal of virology.

[121]  R. Weiss,et al.  The receptor for HIV: dissection of CD4 and studies on putative accessory factors. , 1996, Current topics in microbiology and immunology.

[122]  R. Nibbs,et al.  Cloning and Characterization of a Novel Promiscuous Human β-Chemokine Receptor D6* , 1997, The Journal of Biological Chemistry.

[123]  E. Clercq,et al.  Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist , 2003 .

[124]  O. Schwartz,et al.  Opposite Effects of SDF-1 on Human Immunodeficiency Virus Type 1 Replication , 1999, Journal of Virology.

[125]  R. Pauwels,et al.  Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. , 1995, Journal of medicinal chemistry.

[126]  Pascal Poignard,et al.  Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.

[127]  Dominique Schols,et al.  Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV , 1998, The Journal of Biological Chemistry.

[128]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[129]  A. Trkola,et al.  The CC-Chemokine RANTES Increases the Attachment of Human Immunodeficiency Virus Type 1 to Target Cells via Glycosaminoglycans and Also Activates a Signal Transduction Pathway That Enhances Viral Infectivity , 1999, Journal of Virology.

[130]  D. Littman,et al.  Expression cloning of new receptors used by simian and human immunodeficiency viruses , 1997, Nature.

[131]  C. Combadière,et al.  Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. , 1998, The Journal of biological chemistry.

[132]  A. Trkola,et al.  Enhancement of Human Immunodeficiency Virus Type 1 Infection by the CC-Chemokine RANTES Is Independent of the Mechanism of Virus-Cell Fusion , 1999, Journal of Virology.

[133]  R. Doms,et al.  The CC Chemokine I-309 Inhibits CCR8-dependent Infection by Diverse HIV-1 Strains* , 1998, The Journal of Biological Chemistry.

[134]  E. De Clercq,et al.  Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. , 2001, Antiviral chemistry & chemotherapy.

[135]  G. Joø,et al.  Macrophage tropism: fact or fiction? , 1997, Journal of leukocyte biology.

[136]  C. Power,et al.  Glycosaminoglycans mediate cell surface oligomerization of chemokines. , 1997, Biochemistry.

[137]  Naoki Yamamoto,et al.  A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[138]  E. Fenyö,et al.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.

[139]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[140]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[141]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[142]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[143]  P. Murphy.  International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature , 2002, Pharmacological Reviews.

[144]  T. Chun,et al.  Latent reservoirs of HIV: obstacles to the eradication of virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[145]  Hassan Mohammad Naif,et al.  Cutting Edge: Dichotomous Effects of β-Chemokines on HIV Replication in Monocytes and Monocyte-Derived Macrophages , 1998, The Journal of Immunology.

[146]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[147]  A. Garzino-Demo,et al.  The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection , 1996, Nature Medicine.